{
    "clinical_study": {
        "@rank": "43366", 
        "arm_group": {
            "arm_group_label": "Chinese herb", 
            "arm_group_type": "Experimental", 
            "description": "Chinese herb"
        }, 
        "brief_summary": {
            "textblock": "To investigate in subjects with non-alcoholic fatty liver disease the direct effects of a\n      Chinese herb formula."
        }, 
        "brief_title": "The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine", 
        "completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "condition": "NAFLD( Non-alcoholic Fatty Liver Disease )", 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "1) Liver fat (measured by CT scan) and liver function assessed by liver enzymes levels; 2)\n      Insulin sensitivity measured by HOMA index, oral glucose tolerance test (OGTT) and a\n      euglycaemic hyperinsulinaemic clamp (with stable isotopes) in a subset of the subjects; 3)\n      Plasma lipid profile and non esterified fatty acids (NEFA) concentration; 4) Circulating\n      levels of adipokines."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subjects with NAFLD(nonalcoholic fatty liver disease) (criteria of Society of\n             Hepatology, Chinese Medical Association, 2002.10),\n\n          -  aged 18-65\n\n          -  alcohol consumption less than 40g/week;\n\n          -  liver/spleen (L/S) ratio no more than 1 by CT scan.\n\n        Exclusion Criteria:\n\n          -  ALT more than twice the upper end of the normal range\n\n          -  viral hepatitis\n\n          -  total parenteral alimentation or secondary liver disease such as hepatocirrhosis,\n             autoimmune hepatitis, metabolic liver disease or drug induced liver disease\n\n          -  severe cardiovascular or renal dysfunction\n\n          -  Subjects with diabetes (fasting glucose more than or equal to 7.0mmol/L or\n             postprandial glucose more than or equal to 11.1mmol/L)\n\n          -  Subjects treated with statins"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677325", 
            "org_study_id": "2006-65"
        }, 
        "intervention": {
            "arm_group_label": "Chinese herb", 
            "description": "Chinese herb formula:Huangqi,huanglian,yinchen,ect", 
            "intervention_name": "Chinese herb (YiQiSanJu)", 
            "intervention_type": "Drug", 
            "other_name": "YiQiSanJu Formula"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 4, 2012", 
        "number_of_arms": "1", 
        "official_title": "The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine", 
        "other_outcome": [
            {
                "description": "creatinine(umol/L) ,usea nitrogen(mmol/l) and uric acid(umol/L)(Automatic biochemical analyzer)", 
                "measure": "renal function", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "automatic blood analyzer. White Blood Cell Count:/L; Red Blood Cell Count:/L; Hemoglobin:g/L; Platelets:/L; neutrophilic granulocyte:\uff05.", 
                "measure": "Routine blood", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "automatic urine analyzer. Color,odor,specific gravity,pH,Protein(g/L),Glucose(+-).", 
                "measure": "Routine urine examination", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "automatic stool analyzer. Color, white blood cell(/Visual Fields), red blood cell(/Visual Fields), bacteria(/Visual Fields),occult blood(+-)", 
                "measure": "Routine stool examination", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "automatic electrocardiograph machine", 
                "measure": "electrocardiography", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "diagnostic X-ray apparatus", 
                "measure": "chest x-ray check", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Huashan Hospital, affliated to Fudan University", 
            "last_name": "Wen-Jian Wang, Ph.D,MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "CT imaging has been used to assess hepatic steatosis and has been validated in relation to liver biopsy .The ratio of liver to spleen (L/S ratio) for CT attenuation values is an index, with a L/S ratio<1 considered to represent fatty liver .", 
            "measure": "The CT ratio of liver/spleen", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677325"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Wen-Jian Wang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Body Mass Index,(weight/height^2)", 
                "measure": "BMI(Body Mass Index )", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Liver function enzymes- alanine aminotransferase (ALT,U/L), aspartate aminotransferase (AST,U/L) and \u03b3-glutamyltransferase (GGT,U/L) and total bilirubin (TBI,\u03bcmol/L), albumin/globin (A/G)(Automatic biochemical analyzer)", 
                "measure": "liver function", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Plasma lipids including triglyceride (TG,mmol/L), total cholesterol, low-density lipoprotein (LDL.mmol/L), high-density lipoprotein (HDL,mmol/L), apolipoprotein A (ApoA,mmol/L), apolipoprotein B (ApoB,mmol/L) and lipoprotein (a) (Lp(a),mmol/L). (Automatic biochemical analyzer)", 
                "measure": "lipid profile", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Insulin sensitivity of lipolysis using NEFA concentrations(\u03bcmol/L).(Enzyme-linked immunosorbent assay)", 
                "measure": "NEFA(nonesterified fatty acid)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "HOMA index(FBG*INSULIN/22.5)", 
                "measure": "HOMA index", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "adiponectin(pg/ml,Enzyme-linked immunosorbent assay)", 
                "measure": "adiponectin", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "interleukin 6(pg/ml,Enzyme-linked immunosorbent assay)", 
                "measure": "IL-6(interleukin 6)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "high sensitivity C-reactive protein(mg/L,Enzyme-linked immunosorbent assay)", 
                "measure": "hs-CRP (C-reactive protein)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "tumor necrosis factor-\u03b1(ng/L,Enzyme-linked immunosorbent assay)", 
                "measure": "TNF\u03b1( tumor necrosis factor-\u03b1)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "leptin(ng/ml,Enzyme-linked immunosorbent assay)", 
                "measure": "leptin", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}